Drugs / Sodium Thiosulfate
last change May 2026 re-read 2 minutes ago

Sodium Thiosulfate

Diagnostic / imaging agent targets ACE2, TMPRSS2 via inhibition

Developed for
calcinosis · platinum-induced ototoxicity · dermatomyositis · calcific tendinitis · calciphylaxis · systemic sclerosis · acute coronary syndrome · acute kidney injury
+9 more · calciphylaxis cutis · cardiovascular disorder · COVID-19 · drug-induced hearing loss · hearing loss disorder · intellectual developmental disorder with paroxysmal dyskinesia or seizures · myocardial infarction · end stage renal failure · nephrolithiasis
Investigated by
National Cancer Institute (NCI) · Children's Oncology Group · Fennec Pharma · Insel Gruppe AG, University Hospital Bern · University Medical Center Groningen · Alison Ehrlich
+41 more · Alp Sener · American Regent, Inc. · Australasian Kidney Trials Network · Barnes-Jewish Hospital · Berry Consultants · CHU de Quebec-Universite Laval · Childhood Liver Tumours Strategy Group - SIOPEL · Children's Hospital Medical Center, Cincinnati · City of Hope Medical Center · Genzyme, a Sanofi Company · Hellenic Institute for the Study of Sepsis · Hope Pharmaceuticals · Hyunseok Kang, MD · Loyola University · NRG Oncology · Nantes University Hospital · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Environmental Health Sciences (NIEHS) · Northern Care Alliance NHS Foundation Trust · OHSU Knight Cancer Institute · Oregon Health and Science University · Qilu Hospital of Shandong University · Ramathibodi Hospital · Robyn T. Domsic, MD, MPH · Shanghai Children's Hospital · Shanghai Children's Medical Center · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Soraia Azevedo · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sunnybrook Health Sciences Centre · TRPHARM · The Netherlands Cancer Institute · University Hospital, Limoges · University of Arizona · University of Birmingham · University of Central Florida · University of Sydney · Vantive Health LLC · Waitemata District Health Board · Washington University School of Medicine · Yunnan Cancer Hospital

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Pedmarqsi 2023-05-26 europa.eu
Approved US (FDA) SODIUM THIOSULFATE 1992-02-14 fda.gov

Trials 34 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05756660 Mar 2023 → Jan 2027 drug-induced hearing loss Children's Hospital Medical Center, Cincinnati Suspended No outcome recorded
Phase 12 trials
Phase 1 NCT07218913 Feb 2026 → Jan 2031 expected hearing loss disorder, nongerminomatous germ cell tumor, testicular non-seminomatous germ cell cancer, testicular seminoma City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT02624479 Dec 2018 → May 2019 Insel Gruppe AG, University Hospital Bern Withdrawn No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07407582 May 2026 → Apr 2028 expected head and neck cancer, testicular cancer, thoracic cancer University of Arizona Recruiting No outcome recorded
Phase 1/2 NCT03017963 Oct 2017 → Mar 2018 acute coronary syndrome University Medical Center Groningen Completed No outcome recorded
Phase 214 trials
Phase 2 NCT06672822 Mar 2025 → Aug 2028 expected calcinosis, dermatomyositis, mixed connective tissue disease, systemic sclerosis Robyn T. Domsic, MD, MPH Recruiting No outcome recorded
Phase 2 NCT05877911 May 2023 → Jan 2025 acute kidney injury, malignant epithelial tumor of ovary Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 2 NCT05129748 Feb 2023 → Jan 2027 expected platinum-induced ototoxicity Sunnybrook Health Sciences Centre Recruiting No outcome recorded
Phase 2 NCT05277285 Apr 2022 → Dec 2023 COVID-19 Hellenic Institute for the Study of Sepsis Unknown No outcome recorded
Phase 2 NCT04541355 Oct 2020 → May 2023 hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma Hyunseok Kang, MD Completed No outcome recorded
Phase 2 NCT03582800 Jan 2020 → Jun 2029 expected dermatomyositis, intellectual developmental disorder with paroxysmal dyskinesia or seizures, systemic sclerosis University Hospital, Limoges Recruiting No outcome recorded
Phase 2 NCT04251832 Jan 2020 → Dec 2022 calcific tendinitis Soraia Azevedo Unknown No outcome recorded
Phase 2 NCT02899364 Jul 2018 → Jun 2021 heart failure, myocardial infarction University Medical Center Groningen Unknown No outcome recorded
Phase 2 NCT02538939 Dec 2015 → Sep 2017 calcific tendinitis Nantes University Hospital Completed No outcome recorded
Phase 2 NCT02281006 Jan 2015 → Jan 2017 head and neck cancer CHU de Quebec-Universite Laval Terminated No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03267277 Oct 2017 → Nov 2022 dermatomyositis National Institute of Environmental Health Sciences (NIEHS) Completed No outcome recorded
Phase 38 trials
Phase 3 NCT07281508 Aug 2025 → Mar 2030 expected platinum-induced ototoxicity The Netherlands Cancer Institute Recruiting No outcome recorded
Phase 3 NCT05382338 Feb 2023 → Dec 2029 expected childhood medulloblastoma Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT05018221 Aug 2021 → Dec 2029 expected calciphylaxis cutis University of Sydney Recruiting No outcome recorded
Phase 3 NCT04478292 Mar 2021 → Mar 2027 expected hepatoblastoma Shanghai Children's Medical Center Recruiting No outcome recorded
Phase 3 NCT03150420 May 2017 → Apr 2020 calciphylaxis Hope Pharmaceuticals Terminated No outcome recorded
Phase 3 NCT02527213 Jan 2015 → Aug 2016 calciphylaxis American Regent, Inc. Withdrawn No outcome recorded
Phase 3 NCT00716976 Jun 2008 → Apr 2015 brain neoplasm, childhood germ cell tumor, extragonadal germ cell tumor, liver cancer +4 Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00652132 Dec 2007 → Sep 2017 liver cancer, platinum-induced ototoxicity University of Birmingham Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03639779 Nov 2018 → Dec 2019 calcinosis University of Central Florida Terminated No outcome recorded
Phase not applicable4 trials
NCT06288152 May 2025 → Mar 2027 expected Alp Sener Recruiting No outcome recorded
NCT01369641 Aug 2011 → Mar 2013 cancer Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Terminated No outcome recorded
NCT01008631 Sep 2009 → Aug 2010 kidney failure Insel Gruppe AG, University Hospital Bern Completed No outcome recorded
NCT00568399 Dec 2007 → Nov 2009 cardiovascular disorder Washington University School of Medicine Completed No outcome recorded
Phase not stated1 trial
NCT04132882 platinum-induced ototoxicity TRPHARM Available No outcome recorded
Also used as a comparator or background therapy in 24 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT05232357 Background Mar → May 2022 digestive system neoplasm Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 0 NCT04213794 Background Nov 2019 → Mar 2024 colon carcinoma, desmoplastic small round cell tumor, fallopian tube carcinoma, gastric carcinoma +7 Mayo Clinic Terminated No outcome recorded
Phase 17 trials
Phase 1 NCT04847063 Background Oct 2021 → Dec 2033 expected appendix cancer, ovarian carcinoma, peritoneal carcinomatosis, peritoneal mesothelioma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT04811703 Background Jul 2021 → Jun 2028 expected fallopian tube cancer, ovarian carcinoma, peritoneal carcinomatosis Hospices Civils de Lyon Recruiting No outcome recorded
Phase 1 NCT04292184 Comparator Mar 2021 → Nov 2022 end stage renal failure London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Completed No outcome recorded
Phase 1 NCT04262336 Comparator Feb 2020 → Jul 2022 platinum-induced ototoxicity Decibel Therapeutics Completed No outcome recorded
Phase 1 NCT00571298 Background Nov 2007 → Nov 2011 malignant pleural mesothelioma Brigham and Women's Hospital Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT00397501 Comparator Oct 2013 breast carcinoma, central nervous system neoplasm, chemotherapy-induced toxicity, cognitive disorder OHSU Knight Cancer Institute Withdrawn No outcome recorded
Phase 1/2 NCT00983398 Background Jul 2009 → Dec 2021 childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered, malignant germ cell tumor, medulloblastoma, medulloepithelioma OHSU Knight Cancer Institute Unknown No outcome recorded
Phase 1/2 NCT00293475 Background Oct 2005 → Jan 2022 primary central nervous system lymphoma OHSU Knight Cancer Institute Unknown No outcome recorded
Phase 1/2 NCT00303849 Background Sep 2005 → Mar 2021 anaplastic oligoastrocytoma, anaplastic oligodendroglioma OHSU Knight Cancer Institute Completed No outcome recorded
Phase 28 trials
Phase 2 NCT04282356 Background Sep 2020 → Dec 2026 expected ovarian carcinoma, peritoneal neoplasm Institut du Cancer de Montpellier - Val d'Aurelle Recruiting No outcome recorded
Phase 2 NCT03127774 Background Sep 2017 → Dec 2026 expected adrenal cortex carcinoma, peritoneal carcinomatosis Columbia University Active not recruiting No outcome recorded
Phase 2 NCT03092518 Background Jun 2017 → Apr 2024 gastric adenocarcinoma, gastroesophageal junction adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT02092298 Background May 2014 → May 2020 digestive system cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT01833832 Background Apr 2013 → Aug 2018 adrenal cortex carcinoma, peritoneal carcinomatosis National Cancer Institute (NCI) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03842982 Background May 2019 → Feb 2031 expected ovarian carcinoma Centre Oscar Lambret Active not recruiting No outcome recorded
Phase not applicable2 trials
NCT04764643 Comparator Feb 2020 → Apr 2021 esophageal squamous cell carcinoma Xijing Hospital of Digestive Diseases Completed No outcome recorded
NCT01088555 Comparator Nov 2009 → Dec 2011 nephrolithiasis VA New York Harbor Healthcare System Completed No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 61 sources stand behind the page.

FieldValueCited text
Known as Sodium Thiosulfate Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.” NCT05877911
54

Sodium thiosulfate (STS) is currently used as a cyanide poisoning antagonist and a chemoprotectant against adverse effects of several chemotherapies such as Cisplatin.” NCT03582800

“During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection).” NCT04282356

“Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy.” NCT07407582

sodium thiosulfate 25% will be administered prior to each PIPAC procedure” NCT04811703

“along with an IV perfusion of sodium thiosulfateNCT03842982

NCT04478292

NCT01833832

NCT02281006

NCT01008631

NCT00303849

NCT03639779

NCT05018221

NCT03017963

NCT03127774

NCT05129748

NCT01572844

NCT04847063

NCT02538939

NCT00571298

NCT01088555

NCT04541355

NCT06288152

NCT04132882

NCT00568399

NCT05232357

NCT05382338

NCT00720772

NCT00075387

NCT00983398

NCT04213794

NCT02527213

NCT00238173

NCT04251832

NCT05756660

NCT03267277

NCT03092518

NCT02624479

NCT00074165

NCT00165503

NCT00397501

NCT02899364

NCT05277285

NCT02092298

NCT01918904

NCT01369641

NCT00716976

NCT00165516

NCT06672822

NCT00165555

NCT04764643

NCT03150420

NCT04292184

NCT00293475

NCT00652132

Known as DB-020 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04262336
Known as Pedmark “receiving sodium thiosulfate anhydrous (Pedmark) plus cisplatin-based chemotherapy compared to those receiving cisplatin-based chemotherapy alone.” NCT07218913
Known as Seacalphyx Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%” NCT04292184
Known as Sodium thiosulfate (STS) Sodium thiosulfate (STS)NCT04292184
Known as sodium thiosulfate anhydrous ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218913
Known as sodium thiosulfate pentahydrate injection BP “Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%” NCT04292184
Known as sodium thiosulphate “Arm II (Neoadjuvant and adjuvant cisplatin and sodium thiosulphate): Patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours...” NCT00652132
2

“Another possibility is the use of sodium thiosulphate (Na2S2O3, STS), a major metabolite of H2S, commercially available compound and typically available as the pentahydrate,...” NCT04292184

NCT07281508

Known as STS “Efficacy of Sodium Thiosulfate (STS) compared to placebo, in reducing analgesic requirement in subjects with calcific uremic arteriolopathy (CUA) during an initial 28-day...” NCT02527213
11

“Sodium thiosulfate (STS) is currently used as a cyanide poisoning antagonist and a chemoprotectant against adverse effects of several chemotherapies such as Cisplatin.” NCT03582800

“Chronic treatment and prophylaxis of vessel and soft tissue calcification as well as of renal calculi could be a future indication for sodium thiosulfate (STS).” NCT02624479

“There are several case series that have shown the effectiveness of injecting a chemical compound called sodium thiosulfate (or "STS") into calcinosis lesions.” NCT06672822

“Sodium thiosulfate (STS) is a H2S-donor with known safety and efficacy profile in humans for other diseases, including calciphylaxis and cyanide poisoning.” NCT05277285

“Sodium thiosulfate (STS) has recently been used with success in the treatment of tumoral calcinosis.” PMID 31673978 Nov 2019

“Sodium thiosulfate solution (STS) has been used to neutralize iodine after Lugol's chromoendoscopy” PMID 34371004 Aug 2021

“Sodium thiosulfate (STS) (Na2S2O3) is primarily used to prevent and treat cyanide poisoning.” NCT04251832

“Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate” NCT07281508

“125mg/50ml sodium thiosulfate (STS) solution” NCT03639779

“H2S-donor sodium thiosulfate (STS)” PMID 34534493 Sep 2021

“Sodium Thiosulfate (STS)” NCT04132882

Known as Thiosulfuric Acid Disodium Salt Thiosulfuric Acid Disodium SaltNCT00983398
Action Inhibit “may block Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) entry into the host cells by interrupting Angiotensin-Converting Enzyme-2 (ACE2) and transmembrane...” NCT05277285
Modality Diagnostic / imaging agent “Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent.” NCT05232357
Route Intravenous “Infused IV x 2 days” NCT00074165
Target ACE2 “interrupting Angiotensin-Converting Enzyme-2 (ACE2) and transmembrane protease serine-2 (TMPRSS2)” NCT05277285
Target TMPRSS2 “interrupting Angiotensin-Converting Enzyme-2 (ACE2) and transmembrane protease serine-2 (TMPRSS2)” NCT05277285